SuperworthExicure free cash flow XCUR
Cash from operations less capital spending, by quarter and over the last twelve months, from 2016.
- Last 12 months, to Dec 31, 2025
- n/m
- a quarter missing
- Latest quarter, Q4 FY25
- −$934K
- Fiscal year 2025
- n/a
Exicure's twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q4 FY25, it was −$934K.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2025 | n/a | n/a |
| FY2024 | n/a | n/a |
| FY2023 | −$10.4M | n/a |
| FY2022 | −$35.7M | n/a |
| FY2021 | −$35.8M | n/a |
| FY2020 | −$42.4M | −18160% |
| FY2019 | $235K | n/a |
| FY2018 | −$19.6M | n/a |
| FY2017 | n/a | n/a |
| FY2016 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY25 | −$934K | n/a | n/a | |
| Q3 FY25 | −$3.4M | n/a | n/a | |
| Q4 FY24 | −$845K | n/a | n/a | |
| Q3 FY24 | −$449K | n/a | n/a | |
| Q4 FY23 | −$816K | n/a | −$10.4M | |
| Q3 FY23 | −$1.4M | n/a | −$16.8M | |
| Q2 FY23 | −$4.8M | n/a | −$22M | |
| Q1 FY23 | −$3.3M | n/a | −$26.2M | |
| Q4 FY22 | −$7.3M | n/a | −$35.7M | |
| Q3 FY22 | −$6.5M | −236% | −$42.5M | |
| Q2 FY22 | −$9.1M | n/a | −$31.2M | |
| Q1 FY22 | −$12.8M | n/a | −$33.5M |
Against its peers
Companies in Healthcare nearest Exicure's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| XCURExicure | n/m |
| NEPHNephros | n/m |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 10.3% |
| SPROSpero Therapeutics | n/m |
| Peer median | 10.3% |
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Exicure
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.